<DOC>
	<DOC>NCT02717442</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.</brief_summary>
	<brief_title>Study of OTO-104 in Subjects With Unilateral Meniere's Disease</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject is a male or female aged 18 to 85 years, inclusive. Subject has a diagnosis of definite unilateral Meniere's disease by 1995 AAOHNS criteria. Subject selfreports active, definitive vertigo episodes for the 2 months prior to the study leadin period. Exclusion Criteria includes, but is not limited to: Subject is pregnant or lactating. Subject has a history of immunodeficiency disease. Subject has previously been randomized to a trial of OTO104.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Meniere's Disease</keyword>
	<keyword>Vertigo</keyword>
</DOC>